Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.

Benucci M, Manfredi M, Saviola G, Sarzi-Puttini P, Atzeni F.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):322-3. Epub 2013 Feb 1. No abstract available.

PMID:
23380047
2.

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.

Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH.

Rheumatol Int. 2016 Feb;36(2):295-300. doi: 10.1007/s00296-015-3285-2. Epub 2015 May 31.

3.

Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.

Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H.

Rheumatol Int. 2016 Mar;36(3):349-57. doi: 10.1007/s00296-015-3379-x. Epub 2015 Oct 5.

PMID:
26438386
4.

Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.

Terenzi R, Santoboni G, Bartoloni E, Alunno A, Luccioli F, Gerli R.

Clin Exp Rheumatol. 2015 May-Jun;33(3):445. Epub 2015 Apr 28. No abstract available.

PMID:
25937244
5.

Adalimumab arrests bone loss in the spine and hip of active rheumatoid arthritis patients with osteopenia.

Li H, Liu R, Chi S, Lu Z, Yang L.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):134-5. Epub 2014 Dec 22. No abstract available.

PMID:
25536341
6.

Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.

Epis O, Casu C, Belloli L, Schito E, Filippini D, Muscarà M, Bruschi E.

Rheumatol Int. 2015 Sep;35(9):1569-70. doi: 10.1007/s00296-015-3243-z. Epub 2015 Mar 13. No abstract available.

PMID:
25773656
7.

Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.

Addimanda O, Possemato N, Macchioni P, Salvarani C.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):460-4. Epub 2014 Jun 23.

PMID:
24960220
8.

Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.

Suzuki T, Hirota T, Ogishima H, Umeda N, Kondo Y, Yokosawa M, Miki H, Tsuboi H, Matsumoto I, Sumida T.

Int J Rheum Dis. 2015 Jan;18(1):108-10. doi: 10.1111/1756-185X.12460. Epub 2014 Oct 7. No abstract available.

PMID:
25294091
9.

Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis.

Faillace C, de Carvalho JF.

Rheumatol Int. 2013 Jul;33(7):1909-10. doi: 10.1007/s00296-012-2409-1. Epub 2012 Mar 24. No abstract available.

PMID:
22441966
10.

Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.

Giannitti C, Fineschi I, Frediani B, Fioravanti A, Galeazzi M.

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):816. Epub 2013 Sep 9. No abstract available.

PMID:
24021246
11.
12.

Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.

Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):332-9. doi: 10.1002/acr.22455.

13.

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.

Yokoe I, Nishio S, Sato H, Kobayashi H.

Mod Rheumatol. 2011 Dec;21(6):710-4. doi: 10.1007/s10165-011-0474-z. Epub 2011 Jun 8. No abstract available. Erratum in: Mod Rheumatol. 2012 Aug;22(4):643.

PMID:
21656090
14.

Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.

Sandoo A, Panoulas VF, Toms TE, Smith JP, Stavropoulos-Kalinoglou A, Metsios GS, Gasparyan AY, Carroll D, Veldhuijzen van Zanten JJ, Kitas GD.

J Hum Hypertens. 2011 Nov;25(11):699-702. doi: 10.1038/jhh.2011.36. Epub 2011 Apr 28. No abstract available.

PMID:
21525886
15.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
16.

Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab.

Fusama M, Nakahara H, Hamano Y, Nishide M, Kawamoto K, Hosokawa T, Nozato S, Higa S, Igarashi T, Takeuchi E, Kuroiwa T, Shimaoka Y, Yukioka M, Miura Y, Higashi K, Kuritani T, Maeda K.

Mod Rheumatol. 2013 Mar;23(2):276-83. doi: 10.1007/s10165-012-0674-1. Epub 2012 Jun 6.

PMID:
22669600
17.

Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.

Nagashima T, Maruyama A, Kamata Y, Minota S.

Rheumatol Int. 2012 Jul;32(7):2231-2. doi: 10.1007/s00296-011-2060-2. Epub 2011 Jul 23. No abstract available.

PMID:
21785953
18.

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2012;70(3):195-9. Review.

19.

Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.

Bergström U, Grundtman C, Lundberg IE, Jacobsson LT, Nilsson K, Turesson C.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):883-90. Epub 2014 Oct 2.

PMID:
25287961
20.

Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study.

Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD.

J Am Heart Assoc. 2017 Mar 13;6(3). pii: e005038. doi: 10.1161/JAHA.116.005038.

Supplemental Content

Support Center